Mehta Vimal's Form 4 filing
BioXcel Therapeutics, Inc. (BTAIQ) · filed Jun 6, 2024
- Accession no.
- 0001104659-24-069195
- Filed
- Jun 6, 2024, 8:35 PM ET
- Trade date
- Jun 4-5, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $405.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mehta VimalCIK 0001733369 | Director, Officer (CEO and President), 10% Owner |
| BioXcel LLCCIK 0001651990 | 10% Owner |
| BioXcel Holdings, Inc.CIK 0001811154 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 4, 2024 | Common Stock | SSaleDisposed | −609,221 | – | – | 7,937,529 | Indirect | |
| Jun 4, 2024 | Common Stock | SSaleDisposed | −283,123 | – | – | 283,122 | Indirect | |
| Jun 5, 2024 | Common Stock | SSaleDisposed | −283,122 | – | – | 0 | Indirect | |
| Jun 4, 2024 | Common Stock | SSaleDisposed | −126,014 | $1.63 | −$205,516.23 | 7,811,515 | Indirect | |
| Jun 5, 2024 | Common Stock | SSaleDisposed | −126,014 | $1.58 | −$199,618.78 | 7,685,501 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 4, 2024 | Common Stock | SSaleDisposed | −17,906 | – | – | 120 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.